Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 28, 2005. The document serves as a clarification regarding the company's earnings guidance for the full year 2005, following an inadvertent disclosure of a specific internal estimate during a third-quarter results webcast.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The only financial metric disclosed is the company's earnings per share (EPS) growth guidance.
- 2005 EPS Growth Guidance: Mid-teens percentage growth in constant exchange rate (CER) terms.
- Inadvertently Disclosed Estimate: 79.9p EPS with approximately 17% growth in CER terms (noted as a point estimate subject to change).
Material Changes
There are no material changes to financial results reported in this document. The filing addresses a communication error where a specific point estimate (79.9p EPS) was briefly displayed during a webcast. Management clarifies that this specific number was not intended to replace the broader "mid-teens" guidance range.
Guidance, Outlook, and Risks
Guidance and Outlook: GSK reaffirms its official earnings guidance for 2005 as "mid-teens" EPS percentage growth in constant exchange rate terms. The company emphasizes that the previously shown 17% growth figure was a snapshot estimate dependent on various assumptions that are regularly reviewed.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements under the US Private Securities Litigation Reform Act of 1995. It notes that actual results may differ materially from projections due to risks and uncertainties, referencing the "Risk Factors" section of the 2004 Annual Report for details.
Investor Verification Checklist
- Verify the official "mid-teens" EPS growth guidance against the inadvertently disclosed 17% point estimate.
- Review the 2004 Annual Report for detailed risk factors affecting operations.
- Monitor future announcements for updates on the assumptions underlying the EPS guidance.
- Confirm that no other financial metrics (revenue, debt, cash flow) were updated in this specific filing.